A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Sponsor
Bristol-Myers Squibb
Study ID
NCT06952465
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    As per product label
  • Any biologic treatment for psoriasis — BIOLOGICAL
    According to the product label

Study Details

The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting

Key Dates

First listed
May 1, 2025
Start date
Jan 24, 2025
Status verified
Apr 2025
Primary completion
Nov 30, 2031
Completion
Nov 30, 2031

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants receiving deucravacitinib treatment
  • Arm: Cohort 2
    Participants receiving biologics treatment for psoriasis

Primary Outcome Measure

Participant baseline demographics [ Time Frame: Baseline ]

Related Studies